McKesson Co. (NYSE:MCK) Shares Purchased by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC raised its position in shares of McKesson Co. (NYSE:MCK - Free Report) by 38.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,109 shares of the company's stock after buying an additional 584 shares during the quarter. Kingswood Wealth Advisors LLC's holdings in McKesson were worth $1,202,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Wolff Wiese Magana LLC raised its position in shares of McKesson by 742.9% in the 3rd quarter. Wolff Wiese Magana LLC now owns 59 shares of the company's stock valued at $29,000 after purchasing an additional 52 shares during the last quarter. MidAtlantic Capital Management Inc. purchased a new position in shares of McKesson in the 3rd quarter valued at approximately $29,000. RPg Family Wealth Advisory LLC purchased a new position in shares of McKesson in the 3rd quarter valued at approximately $31,000. ORG Wealth Partners LLC purchased a new position in shares of McKesson in the 3rd quarter valued at approximately $40,000. Finally, Bruce G. Allen Investments LLC raised its position in shares of McKesson by 51.9% in the 4th quarter. Bruce G. Allen Investments LLC now owns 82 shares of the company's stock valued at $47,000 after purchasing an additional 28 shares during the last quarter. 85.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other McKesson news, EVP Leann B. Smith sold 579 shares of McKesson stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total transaction of $331,645.41. Following the sale, the executive vice president now owns 864 shares of the company's stock, valued at $494,890.56. The trade was a 40.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.11% of the stock is owned by insiders.

McKesson Price Performance

NYSE MCK traded down $9.75 on Friday, hitting $594.85. The company had a trading volume of 786,879 shares, compared to its average volume of 659,902. The company has a market capitalization of $75.51 billion, a PE ratio of 30.81, a PEG ratio of 1.30 and a beta of 0.52. The company's fifty day moving average price is $591.35 and its 200-day moving average price is $562.12. McKesson Co. has a 12-month low of $464.42 and a 12-month high of $637.51.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, topping the consensus estimate of $6.88 by $0.19. The company had revenue of $93.65 billion during the quarter, compared to analyst estimates of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The firm's revenue was up 21.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.23 EPS. On average, sell-side analysts anticipate that McKesson Co. will post 32.72 EPS for the current year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 0.48%. The ex-dividend date is Monday, March 3rd. McKesson's payout ratio is presently 14.71%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on MCK. Wells Fargo & Company increased their price target on shares of McKesson from $535.00 to $641.00 and gave the stock an "equal weight" rating in a report on Friday, December 13th. Citigroup cut their price target on shares of McKesson from $713.00 to $677.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Mizuho began coverage on shares of McKesson in a report on Wednesday, December 4th. They issued a "neutral" rating and a $630.00 price target on the stock. Morgan Stanley increased their price target on shares of McKesson from $612.00 to $642.00 and gave the stock an "overweight" rating in a report on Tuesday, December 17th. Finally, StockNews.com upgraded shares of McKesson from a "hold" rating to a "buy" rating in a report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, McKesson presently has a consensus rating of "Moderate Buy" and a consensus price target of $646.14.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.